INFECTIONS

Brand Owner (click to sort) Address Description
CYTOMX CytomX Therapeutics, Inc. 151 Oyster Point Blvd, Suite 400 South San Francisco CA 94080 infections, inflammation; infections, inflammation; infections, inflammation; engineered cell therapies for medical purposes, namely, for use in treating cancer, infections, autoimmunity, and inflammation; infections, inflammation; assays and reagents for use in medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; biochemical test kits comprised of assays and reagents for medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, medical diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments for medical purposes; therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens;Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic kits for scientific, laboratory, and research use comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research use;Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy, proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific and medical research purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical scientific research consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer network;
INFECTIONS LIMITED Infections Limited P.S. 1624 SOUTH I ST. #305 Tacoma WA 98405 INFECTIONS;providing medical services to cure infections and to prevent infections;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention is directed to a lipid-based delivery system for administration of an active drug substance selected from lysolipid derivatives which are particularly useful in the treatment or detection of parasitic infections, especially parasitic infections which cause an elevated PLA2 level in the infected mammal. Preferred parasitic infections are infections wherein the life cycle of the parasite involves the liver and/or spleen of the infected organism.